FOLH1 and prostate cancer: With 177Lu-PSMA-617 shown to be safe and non-inferior in treatment to docetaxel, 177LU-PSMA-617 could be used for treatment earlier rather than being reserved for advanced end-stage metastatic castration-resistant prostate cancer [26].